Back

Age-Related differences in compliance and wearing time of wearable cardioverter defibrillators: a monocentric retrospective observational study

31 March 2025 (08:00 - 17:45)
Organised by: Logo
Congress Presentation Part of: Poster session 2: arrhythmia mechanisms, device therapy, and ventricular arrhythmias Device Treatment EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Mr Enriko Kurti

Clinic Fuerth, Fuerth (Germany)

146 More presentations in this session

Presentation thumbnail
Impact of ICD and CRT-D implantation on survival in ischemic and non-ischemic cardiomyopathy: a single-center croatian retrospective cohort study and comparative insights with the DANISH trial
Assistant Professor M. Puljevic (Zagreb, HR)
Abstract
Presentation thumbnail
Do the longer leadless pacemakers with helix screws affect tricuspid regurgitation after pacemaker implantation?
Presentation thumbnail
Classification of atrial fibrillation burden pattern in cardiac implantable electronic devices
Mr S. Majumder (Minneapolis, US)
Abstract Slides Video
Presentation thumbnail
Life-threatening arrhythmia in patients with suspected acute myocarditis
Miss K. Bulatova (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Early outcomes of left bundle branch area pacing upgrade in pediatric pacing-induced cardiomyopathy
Mr Y. Turubayev (Astana, KZ)
Abstract Slides Video

Access the full session

Session thumbnail
Poster session 2: arrhythmia mechanisms, device therapy, and ventricular arrhythmias

The Event

Event poster

EHRA 2025

31 March 2025 08:00 CET
You may be interested in
thumbnail
Congress Presentation
Wearable cardioverter-defibrillator compared to beta blockers in patients at risk of sudden death: a real-world propensity score-matched study.
thumbnail
Congress Presentation
Real-world single center experience with the wearable cardioverter defibrillator: sex differences in risk stratification for sudden cardiac death
thumbnail
Congress Presentation
Equal performance of the subcutaneous and transvenous implantable cardioverter defibrillator across all age groups in the PRAETORIAN trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources